Pfizer Inc. (PFE) is my Top Pick for income-oriented investors in 2025. The past year was unkind to the pharmaceutical giant because it does not have diabetes or weight loss drugs in its portfolio.

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare ...

STORY: Pfizer posted a better than expected fourth quarter profit on Tuesday (Feb 4).It was helped by cost cuts and a smaller-than-feared drop in sales of its COVID-19 vaccine.Pfizer's shares rose ...

This month, Daniel Ghinn examines a 'ground-breaking' multichannel campaign from Pfizer, which puts engagement and trust-building ahead of pushing products ... that has been viewed more than ...

Other relevant products are Prevnar 13 ... the stock might be too cheap to ignore. Pfizer does not rank on our latest list of the 31 Most Popular Stocks Among Hedge Funds. As per our database ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE)) stands against other undervalued defensive ...